AMNEAL PHARMS
GenericsAMNEAL PHARMS is a generic drug manufacturer focused on Cardiovascular, Neurology, Infectious Disease.
AMNEAL PHARMS at a Glance
- Strong track record with 85% execution quality across 11 trials
- Fast trial execution (8 months median completion)
AMNEAL PHARMS's Key Drugs
AMNEAL PHARMS's core commercial portfolio centers on PRASUGREL, DICLOFENAC SODIUM AND MISOPROSTOL, BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.
Thrombotic Cardiovascular Events
Osteoarthritis
Opioid Dependence
AMNEAL PHARMS's Recent FDA Approvals
AMNEAL PHARMS secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
AMNEAL PHARMS's Therapeutic Areas
AMNEAL PHARMS's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
AMNEAL PHARMS's Top Competitors
AMNEAL PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, AbbVie, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
AMNEAL PHARMS Pipeline Snapshot
Active clinical trials for AMNEAL PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • PRASUGREL leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 6/7 completed
- • Speed: 8 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (5)
Discontinued (5)
Company Info
- First Approval
- 2002-06-20
- Latest
- 2026-06-18
- Applications
- 172
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges